NCT04631432 is a clinical trial of Pre-screening in Autism Spectrum Disorder (ASD), sponsored by Technion, Israel Institute of Technology.

Who is sponsoring NCT04631432?

NCT04631432 is sponsored by Technion, Israel Institute of Technology.

What drugs are being tested in NCT04631432?

Interventions in NCT04631432: Pre-screening, Task session.

What condition does NCT04631432 study?

NCT04631432 studies Autism Spectrum Disorder (ASD).

Is NCT04631432 still recruiting?

NCT04631432 is currently completed. Last updated 27 April 2022.

Last reviewed 2022-04-27 · How we verify

NCT04631432

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Choice Switching and Autism

Completed Last updated 27 April 2022

What this trial tests

trial testing Pre-screening in Autism Spectrum Disorder (ASD) in 114 participants. Completed in 13 September 2021.

Timeline

1 January 2021

Primary endpoint
13 August 2021

13 September 2021

Quick facts

Lead sponsor	Technion, Israel Institute of Technology
Status	Completed
Study type	OBSERVATIONAL
Enrollment	114
Start date	1 January 2021
Primary completion	13 August 2021
Estimated completion	13 September 2021
Sites	1 location across Israel

Drugs / interventions tested

Pre-screening
Task session

Conditions studied

Autism Spectrum Disorder (ASD) — all drugs for Autism Spectrum Disorder (ASD) →

Sponsor

Technion, Israel Institute of Technology

Who can join

18 and older, any sex, with Autism Spectrum Disorder (ASD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to replicate and clarify a recently observed phenomenon whereby individuals with Autism Spectrum Disorder (ASD) switch between options in a repeated task to a greater extent than healthy controls do. In a meta-analysis a large effect size was found (.37) yet because the effect was noisy in different studies it was not statistically significant. The investigators seek to first examine a very large population through an Internet mediated platform. The sample size will be about the size of all of the previous studies that examined this issue together. Secondly, the investigators wish to understand the discrepancy between this choice switching phenomenon and the recorded tendency of ASD individuals to avoid changing choices. First, the investigators will administer the task in which the effect was found (the Iowa Gambling task) for a longer duration than previously and evaluate whether ASD individuals show increased choice switching in the first blocks of trials but reduced switching following more experience. Secondly, the investigators will administer an additional block of trials without feedback in which participants will not be able to go through a learning process. The investigators predict that this will reduce (and possible flip) the tendency of individuals with ASD to switch choices more often.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Choice behavior in autistic adults: What drives the extreme switching phenomenon?
Zeif D, Yakobi O, Yechiam E. · · 2023 · cited 3× · PMID 36862653 · DOI 10.1371/journal.pone.0282296

Verify or expand the search:

Other recruiting trials for Autism Spectrum Disorder (ASD)

Currently open trials in the same condition.

NCT07421830 — An Empowering Parent Training Intervention to Increase Physical Activity in Preschool Aged Children With Autism · NA · recruiting
NCT07495761 — Prospective Study to Determine the Prevalence of Signs of Central Sensitization in Adults With ASD Without Intellectual · recruiting
NCT07276750 — Coaching and Leadership in Autism Support Settings · NA · recruiting
NCT07304440 — Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study · Phase 1, PHASE2 · recruiting
NCT07189442 — L-theanine and Paraxanthine for Cognitive Improvement in Adults With ADHD and ASD · NA · recruiting

Other Technion, Israel Institute of Technology trials

Trials by the same sponsor.

NCT05001594 — Wearable Vibration Effect on Biomechanics and Biomarkers After ACL Reconstruction · NA · completed
NCT06766084 — Is Total Arterial Revascularization Superior to Multiarterial Grafting in Coronary Artery Bypass Grafting · completed
NCT06766123 — Outcomes of Coronary Artery Bypass Grafting in Israeli Jews and Arabs · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04631432 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Technion, Israel Institute of Technology
Last refreshed: 27 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04631432.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing